Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filsuvez in Moderate-to-Severe Epidermolysis Bullosa Simplex
NCT07756138Phase 2Not yet recruiting
- Sponsor
- Stanford University
- Start
- Oct 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
A Phase 2 trial of Birch bark extract in epidermolysis bullosa simplex (EBS), sponsored by Stanford University. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
Birch bark extract
03
Conditions
epidermolysis bullosa simplex (EBS)
Beyond the preview
Go deeper on NCT07756138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07756138.